BRAF and neoplasm: BRAF inhibition with encorafenib 6 mg/kg (green curves) did not change tumor growth compared to the sham-treated control mice (black curves), whereas the use of the MEK inhibitor binimetinib (8 mg/kg) significantly diminished tumor growth in all three models.